Troponin News and Research

RSS

Roche Diagnostics introduces STAT immunoassays for cardiac biomarker testing

Roche Diagnostics announced today that it has introduced a complete battery of STAT immunoassays for cardiac biomarker testing on the cobas 6000 analyzer series, an integrated system designed for diagnostic labs with medium testing volumes.

From Roche Sequencing and Life Science 17 Sep 2010

Running continuously over 50 or 100 miles may not be good for the heart: Study

In 2009, a study was conducted in UK by Liverpool John Moores University and the Countess of Chester Hospital to assess the effects of running in ultra-endurance races. Typically aimed at super-fit and experienced athletes, these races are held over distances exceeding 50 miles (80 kilometres). The conclusions suggest that some damage is likely to occur to the heart muscle of competitors, while 12 percent of the study group showed signs of significant cardiac damage.

31 Aug 2010

Improvement of postoperative care decreases myocardial ischemia and major cardiac events

A study published in the October 2010 issue of Anesthesiology is among the first to show that the quality of immediate postoperative care of orthopedic surgery patients has important effects on patients' long-term cardiac outcomes.

25 Aug 2010

Abbot's innovative solutions to be highlighted at AACC

A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.

27 Jul 2010

CardioGenics Holdings' subsidiary signs second product agreement with Merck Chimie

CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company's subsidiary, CardioGenics Inc., has entered into an agreement with Merck Chimie S.A.S. to adopt its proprietary biological-linking technology to Merck-supplied magnetic beads designed to increase yields in antibody manufacturing.

15 Jul 2010

CardioGenics announces clinical test sites for QL Care portable blood analyzer

CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced the selection of four sites for clinical testing of its patented QL Care™ Analyzer, a portable diagnostic platform designed to produce test results with central lab-like accuracy in 15 minutes using whole blood.

21 Jun 2010

2,300 researchers under one roof at American Society of Echocardiography 21st Annual Scientific Sessions

Research released today at the American Society of Echocardiography (ASE) 21st Annual Scientific Sessions unveiled findings that will have a significant impact on the diagnosis and treatment of heart disease and the application of echocardiography in the future.

15 Jun 2010

OXiGENE reports positive final data from Phase 1 study of OXi4503 in patients with solid tumors

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that in collaboration with OXiGENE, Professor Gordon Rustin and colleagues from the Mount Vernon Cancer Research Centre, UK and other institutions in the United Kingdom, reported positive final data from an investigator-sponsored Phase 1 study of OXi4503 in patients with solid tumors.

7 Jun 2010

Data on Nanosphere Verisens PSA assay to be presented at AUA annual meeting

At the annual meeting of the American Urological Association, data using the Nanosphere Verisens™ ultra-sensitive PSA assay (research use only) will be highlighted as one of less than 40 abstracts that were singled out by the Association for a special session for journalists.

3 Jun 2010

Cardiola's m.pulse MCP based system improves cardiac function in stable CHF patients

Cardiola AG announced today that the Company's CE-Marked m.pulse® Muscular CounterPulsation ("MCP")-based system demonstrated "an immediate improvement of cardiac output with non-invasive means" in a patient population of advanced yet stable chronic heart failure. The effects could be shown in 22 patients over three consecutive days.

24 Apr 2010

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.

9 Mar 2010

Cardiac marker POC test: A successful concept of point-of-care diagnostics

Cardiac marker POC tests are now widely used in hospitals and have emerged as a successful model of the concept of point-of-care diagnostics, according to a new report from Kalorama Information. The 2008 world market for POC cardiac enzymes and tests is estimated at $490 million, and growing at 12% a year for the past three years, according to "Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads," from healthcare market research publisher Kalorama Information.

24 Dec 2009

Cardiac myosin-binding protein C identified as potential new diagnostic biomarker for heart attacks

Though they remain a leading killer, heart attacks can be effectively treated provided they can be rapidly diagnosed following initial onset of symptoms. In a study appearing in this month's Molecular and Cellular Proteomics, researchers have identified cardiac myosin-binding protein C (cMyBP-C) as a potential new diagnostic biomarker for heart attacks, one that may be particularly valuable for mild attacks in which traditional diagnostic proteins may not be abundant enough.

11 Dec 2009

New IME-developed cardiac biomarker testing system saves time

Scientists at Singapore's Institute of Microelectronics (IME) have developed a rapid and sensitive integrated system to test simultaneously for specific cardiac biomarkers in finger prick amount of blood.

9 Dec 2009

Non-clinical data of CK-2017357 presented by Cytokinetics

Cytokinetics, Incorporated announced today that both a poster and an oral presentation summarizing non-clinical data regarding CK-2017357, a novel fast skeletal troponin activator, were presented at the 5th Cachexia Conference, organized by the Society on Cachexia and Wasting Disorders, being held December 5-8, 2009 in Barcelona, Spain.

8 Dec 2009

Study reveals high levels of cardiac biomarkers in the blood of heart attack patients

Many heart attack patients have high levels of cardiac biomarkers in the blood for several months after leaving the hospital, with more shortness of breath and chest pain, according to a Henry Ford Hospital study.

24 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Financial results for third-quarter 2009 announced by Spectral Diagnostics

Spectral Diagnostics Inc., today announced its financial results for the third quarter ended September 30, 2009.

12 Nov 2009

Thermo Fisher Scientific announces the availability of its Copeptin assay in Europe

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the availability in Europe of its new Copeptin assay, which helps medical personnel quickly and accurately diagnose acute myocardial infarction (AMI), commonly known as a heart attack.

From Thermo Fisher Scientific Inc. 26 Oct 2009

Study reveals elevated cTnT levels in post-CABG patients

Levels of a biomarker used in the diagnosis of heart attacks are almost universally elevated in patients who have undergone coronary-artery bypass grafting (CABG) and, when markedly elevated, are powerfully prognostic, a team of researchers from the Massachusetts General Hospital (MGH) Heart Center has found.

5 Sep 2009